Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients

Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our ele...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2013-11, Vol.19 (1), p.117-23
Main Authors: Reliquet, Véronique, Chirouze, Catherine, Allavena, Clotilde, Muret, Patrice, Peytavin, Gilles, André-Garnier, Elisabeth, Bettinger, Dominique, Ferré, Virginie, Hoen, Bruno, Raffi, François
Format: Article
Language:English
Subjects:
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Drug Combinations
Drug Substitution
Female
Follow-Up Studies
HIV Infections
HIV-1
Humans
Life Sciences
Male
Microbiology and Parasitology
Middle Aged
Nevirapine
Protease Inhibitors
Pyrrolidinones
Retrospective Studies
Reverse Transcriptase Inhibitors
Risk Factors
Treatment Outcome
Viral Load
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our electronic database all patients with HIV RNA6 months on an NVP-containing regimen and no prior exposure to integrase strand transfer inhibitors who were switched to RAL plus NVP. Data was collected for 36 months or until discontinuation of RAL plus NVP for any reason. A total of 39 patients (30 male) were included in this analysis. Median duration of prior antiretroviral therapy was 14 years (IQR 10-17) and median duration with plasma HIV-1 RNA
ISSN:1359-6535